TIDMRTW
RNS Number : 1453G
RTW Biotech Opportunities Ltd
17 July 2023
LEI: 549300Q7EXQQH6KF7Z84
17 July 2023
RTW Biotech Opportunities Ltd
Portfolio Company Update: Apogee Therapeutics IPO
Apogee executes successful $300 million IPO
RTW Biotech Opportunities Ltd (the "Company"), a London Stock
Exchange-listed investment company focused on identifying
transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors, is pleased to
note the announcement by one of its portfolio companies, Apogee
Therapeutics, Inc. ("Apogee") regarding its pricing of an upsized
$300 million initial public offering ("IPO") and admission to trade
on Nasdaq Global Market under ticker "APGE".
Apogee is a pre-clinical biotechnology company seeking to
develop differentiated biologics for the treatment of atopic
dermatitis ("AD"), chronic obstructive pulmonary disease ("COPD"),
and other inflammatory and immunology indications with high unmet
need. Its two lead product candidates, APG777 and APG808, are being
developed for the treatment of AD and COPD.
Prior to IPO, the Company, together with other funds managed by
RTW Investments, LP (the "Investment Manager"), co-led Apogee's
$149 million Series B financing round in December 2022.
Apogee's IPO raised $300 million by offering 17,650,000 shares
at $17.00 per share. On the first day of trading, Apogee's share
price traded up by 24.9% to close at $21.23 per share. At 30 June
2023, Apogee represented 0.6% of the Company's NAV.
Roderick Wong, MD, Managing Partner and Chief Investment Officer
at the Investment Manager, said:
"Despite challenging capital markets, we continue to see good
companies backed by promising science resonate with investors.
Apogee's IPO is the third in our portfolio so far this year (and
fifth go-public event). As full life cycle investors, we are
excited to continue to partner with the team in its efforts to
develop new treatments for patients with inflammatory conditions.
We also hope that such a strong market debut from a pre-clinical
company may presage a better IPO environment ahead."
Apogee's IPO pricing announcement can be accessed on its website
at: www.apogeetherapeutics.com.
For Further Information
RTW Investments, LP +44 (0)20 7959 6361
Woody Stileman, Managing Director
Krisha McCune, Director, Client Service
biotechopportunities@rtwfunds.com
Buchanan Communications +44 (0)20 7466 5107
Charles Ryland
Henry Wilson
Numis +44 20 7260 1000
Freddie Barnfield
Nathan Brown
Euan Brown
BofA Securities +44 20 7628 1000
Edward Peel
Kieran Millar
Cadarn Capital
David Harris +44 73 6888 3211
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an
investment fund focused on identifying transformative assets with
high growth potential across the life sciences sector. Driven by a
long-term approach to support innovative businesses, RTW Biotech
Opportunities Ltd invests in companies developing next-generation
therapies and technologies that can significantly improve patients'
lives.
RTW Biotech Opportunities Ltd is managed by RTW Investments, LP,
a leading healthcare-focused entrepreneurial investment firm with
deep scientific expertise and a strong track record of supporting
companies developing life-changing therapies.
Visit the RTW website at www.rtwfunds.com for more
information.
***********
The information in this announcement may include forward-looking
statements, which are based on the current expectations and
projections about future events, and in certain cases can be
identified by the use of terms such as "may", "will", "should",
"expect", "anticipate", "project", "estimate", "intend",
"continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are
subject to risks, uncertainties and assumptions about the Company
and/or its underlying investments, including, among other things,
the development of the applicable entity's business, trends in its
operating industry, expected use of financing proceeds and future
capital expenditures and acquisitions. In light of these risks,
uncertainties and assumptions, the events in the forward-looking
statements may not occur.
The information contained in this announcement is given at the
date of its publication (unless otherwise marked). No reliance may
be placed for any purpose whatsoever on the information or opinions
contained in this announcement or on its completeness, accuracy or
fairness.
***********
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PFUXQLFFXDLEBBB
(END) Dow Jones Newswires
July 17, 2023 02:00 ET (06:00 GMT)
Rtw Biotech Opportunities (LSE:RTWG)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 3월(3) 2025
Rtw Biotech Opportunities (LSE:RTWG)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 3월(3) 2025
